BTIG analyst David Larsen lowered the firm’s price target on Astrana Health (ASTH) to $50 from $70 and keeps a Buy rating on the shares. The company could face headwinds from higher cost trends, though it has already provided favorable comments around Q2 results, the analyst tells investors in a research note. There have been some worries about home-health reimbursement, but the specialty medical trend and home-health and rehab volumes will likely far offset these worries, the firm added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health’s Strategic Acquisition and Financial Guidance Boost: Analyst Recommends Buy
- Astrana Health Completes Acquisition of Prospect Health
- Astrana Health management to meet with Truist
- Astrana Health Approves 2024 Equity Incentive Plan
- Astrana Health Updates Corporate Presentation for Conferences